JP7013446B2 - Ｇａｂａ（ａ）受容体モジュレーター、及び、喘息における気道過敏及び炎症を抑制するための方法 - Google Patents

Ｇａｂａ（ａ）受容体モジュレーター、及び、喘息における気道過敏及び炎症を抑制するための方法 Download PDF

Info

Publication number
JP7013446B2
JP7013446B2 JP2019508255A JP2019508255A JP7013446B2 JP 7013446 B2 JP7013446 B2 JP 7013446B2 JP 2019508255 A JP2019508255 A JP 2019508255A JP 2019508255 A JP2019508255 A JP 2019508255A JP 7013446 B2 JP7013446 B2 JP 7013446B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
compound according
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019508255A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528267A5 (enExample
JP2019528267A (ja
Inventor
アーノルド，アレクサンダー・イー
スタッフォード，ダグラス・シー
クック，ジェームズ・エム
エマラ，チャールズ・ダブリュー
フォルクオ，グロリア
ジャハーン，ラジワナ
コダリ，レヴァティ
リー，グワングワン
スティーヴン，マイケル・ラジェシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of JP2019528267A publication Critical patent/JP2019528267A/ja
Publication of JP2019528267A5 publication Critical patent/JP2019528267A5/ja
Application granted granted Critical
Publication of JP7013446B2 publication Critical patent/JP7013446B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019508255A 2016-08-16 2017-08-16 Ｇａｂａ（ａ）受容体モジュレーター、及び、喘息における気道過敏及び炎症を抑制するための方法 Active JP7013446B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662375694P 2016-08-16 2016-08-16
US62/375,694 2016-08-16
US201662427771P 2016-11-29 2016-11-29
US62/427,771 2016-11-29
PCT/US2017/047185 WO2018035246A1 (en) 2016-08-16 2017-08-16 Gaba(a) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma

Publications (3)

Publication Number Publication Date
JP2019528267A JP2019528267A (ja) 2019-10-10
JP2019528267A5 JP2019528267A5 (enExample) 2020-09-24
JP7013446B2 true JP7013446B2 (ja) 2022-02-15

Family

ID=59714151

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019508255A Active JP7013446B2 (ja) 2016-08-16 2017-08-16 Ｇａｂａ（ａ）受容体モジュレーター、及び、喘息における気道過敏及び炎症を抑制するための方法

Country Status (8)

Country Link
US (2) US11447495B2 (enExample)
EP (1) EP3500573B1 (enExample)
JP (1) JP7013446B2 (enExample)
CN (1) CN109790170B (enExample)
AU (1) AU2017313753B2 (enExample)
CA (1) CA3033964A1 (enExample)
ES (1) ES2895965T3 (enExample)
WO (1) WO2018035246A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115380034A (zh) * 2020-03-31 2022-11-22 豪夫迈·罗氏有限公司 作为GABA Aγ1 PAM的苯并二氮杂䓬衍生物
EP3901155A1 (en) * 2020-04-20 2021-10-27 F. Hoffmann-La Roche AG New benzodiazepine derivatives as gaba a gamma1 pam
WO2023052312A1 (en) 2021-09-29 2023-04-06 F. Hoffmann-La Roche Ag New benzodiazepine derivatives as gaba a gamma1 pam
WO2023057415A1 (en) 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as positive allosteric modulators of the gaba a gamma1 receptor

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015129A1 (en) 1994-11-11 1996-05-23 F. Hoffmann-La Roche Ag Oxazolyl- and thiazolylimidazo-benzo- and thienodiazepines and their use as medicaments
US20060003995A1 (en) 2004-06-30 2006-01-05 Wisys Technology Foundation, Inc. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
US20060258643A1 (en) 2005-05-16 2006-11-16 Wisys Technology Foundation, Inc. Gabaergic agents to treat memory deficits
JP2008502736A (ja) 2004-06-09 2008-01-31 アバニール・ファーマシューティカルズ 高脂血症および関連疾患の治療のための複素環式誘導体
US20120295892A1 (en) 2011-04-28 2012-11-22 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses
JP2014515374A (ja) 2011-05-23 2014-06-30 エラン ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Ｌｒｒｋ２キナーゼ活性の阻害剤
JP2014532749A (ja) 2011-11-11 2014-12-08 アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． β２アドレナリン受容体アゴニストおよびＭ３ムスカリン受容体アンタゴニスト活性を有する新規シクロヘキシルアミン誘導体
JP2015503596A (ja) 2012-01-13 2015-02-02 北京盛諾基医薬科技有限公司Ｂｅｉｊｉｎｇ Ｓｈｅｎｏｇｅｎ Ｐｈａｒｍａ Ｇｒｏｕｐ Ｌｔｄ． ポリヒドロキシベンゾピランケトン化合物の合成およびその抗腫瘍効果
JP2015529254A (ja) 2012-09-21 2015-10-05 ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド 喘息における気道の過敏症及び炎症を制御するための新規なｇａｂａａアゴニスト及び使用方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA755418B (en) 1974-09-11 1977-06-29 Hoffmann La Roche Diazepine derivatives
US4125726A (en) 1977-03-11 1978-11-14 Hoffmann-La Roche Inc. Imidazo[1,5-a][1,4]benzodiazepines
US4401597A (en) 1978-05-15 1983-08-30 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
US4226768A (en) * 1979-05-29 1980-10-07 Hoffmann-La Roche Inc. Process for the preparation of imidazobenzodiazepines
US4238610A (en) 1979-12-20 1980-12-09 Hoffmann-La Roche Inc. Intermediates for the production of imidazobenzodiazepines
ZA845757B (en) 1983-08-25 1985-04-24 Hoffmann La Roche Benzodiazepine derivatives
US5317018A (en) 1992-06-09 1994-05-31 Armin Walser Benzodiazepines and compositions for treating anxiety and panic disorders, and idiopathic and psychomotor epilepsy
CA2184802C (en) 1995-10-10 2007-07-31 Karl-Heinz Bender Process for manufacture of imidazo benzodiazepine derivatives
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
US20010014738A1 (en) 1999-06-30 2001-08-16 Madhup K. Dhaon Process for the preparation of imidazodiazepine intermediates
US6512114B1 (en) 1999-06-30 2003-01-28 Abbott Laboratories Process for the preparation of Midazolam
US6262260B1 (en) 2000-03-23 2001-07-17 Abbott Laboratories Process for the preparation of midazolam
KR100865410B1 (ko) 2002-03-28 2008-10-24 위시스 테크놀로지 파운데이션, 인크. 진정 및 운동실조 효과가 감소된 항불안제
US8835424B2 (en) 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
US8119629B2 (en) 2007-10-03 2012-02-21 Bristol-Meyers Squibb Company Carboxamide GABAA α2 modulators
US20100261711A1 (en) 2009-03-20 2010-10-14 Wisys Technology Foundation Selective anticonvulsant agents and their uses
IT1399764B1 (it) 2010-05-04 2013-05-03 F S I Fabbrica Italiana Sint Procedimento per la sintesi di 4h-imidazo [1,5-a][1,4]benzodiazepine, in particolare di midazolam.
CN103319486B (zh) 2012-03-22 2017-10-10 徐州市心血管病研究所 合成4H‑咪唑并[1,5‑a][1,4]苯二氮卓,特别是咪达唑仑的方法
SI3439665T1 (sl) 2016-03-18 2023-05-31 Uwm Research Foundation, Inc. Zdravljenje kognitivnih simptomov in simptomov razpoloženja pri nevrodegenerativnih in nevropsihiatričnih motnjah z agonisti receptorja GABAA, ki vsebujejo ALFA5

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015129A1 (en) 1994-11-11 1996-05-23 F. Hoffmann-La Roche Ag Oxazolyl- and thiazolylimidazo-benzo- and thienodiazepines and their use as medicaments
JP2008502736A (ja) 2004-06-09 2008-01-31 アバニール・ファーマシューティカルズ 高脂血症および関連疾患の治療のための複素環式誘導体
US20060003995A1 (en) 2004-06-30 2006-01-05 Wisys Technology Foundation, Inc. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
US20060258643A1 (en) 2005-05-16 2006-11-16 Wisys Technology Foundation, Inc. Gabaergic agents to treat memory deficits
US20120295892A1 (en) 2011-04-28 2012-11-22 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses
JP2014515374A (ja) 2011-05-23 2014-06-30 エラン ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Ｌｒｒｋ２キナーゼ活性の阻害剤
JP2014532749A (ja) 2011-11-11 2014-12-08 アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． β２アドレナリン受容体アゴニストおよびＭ３ムスカリン受容体アンタゴニスト活性を有する新規シクロヘキシルアミン誘導体
JP2015503596A (ja) 2012-01-13 2015-02-02 北京盛諾基医薬科技有限公司Ｂｅｉｊｉｎｇ Ｓｈｅｎｏｇｅｎ Ｐｈａｒｍａ Ｇｒｏｕｐ Ｌｔｄ． ポリヒドロキシベンゾピランケトン化合物の合成およびその抗腫瘍効果
JP2015529254A (ja) 2012-09-21 2015-10-05 ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド 喘息における気道の過敏症及び炎症を制御するための新規なｇａｂａａアゴニスト及び使用方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
J. Heterocyclic Chem.，1986年，Vol. 23，pp. 1303-1314
J. Med. Chem.，1989年，Vol. 32，pp. 2282-2291
SYNTHESIS，2004年，No. 16，pp. 2697-2703
周東智，有機医薬分子論，2012年，p.201-18
野崎正勝 等，創薬化学，第１版，株式会社化学同人，1995年，p.98-99
長野哲雄、夏苅英昭、原博，創薬化学，第1版第4刷，日本，2007年04月10日，pp. 139-140

Also Published As

Publication number Publication date
US12054491B2 (en) 2024-08-06
US20230103216A1 (en) 2023-03-30
EP3500573A1 (en) 2019-06-26
AU2017313753B2 (en) 2022-01-27
AU2017313753A1 (en) 2019-03-07
US20210284649A1 (en) 2021-09-16
CN109790170B (zh) 2022-08-02
US11447495B2 (en) 2022-09-20
WO2018035246A1 (en) 2018-02-22
CN109790170A (zh) 2019-05-21
CA3033964A1 (en) 2018-02-22
BR112019003065A2 (pt) 2019-05-21
ES2895965T3 (es) 2022-02-23
JP2019528267A (ja) 2019-10-10
EP3500573B1 (en) 2021-10-06

Similar Documents

Publication Publication Date Title
US12054491B2 (en) Substituted benzo[f]imidazo[1,5-a][1,4]diazepines as GABA(a) receptor modulators
JP5874878B2 (ja) 複素二環スピロ化合物又はその薬学的に許容される塩、これらの化合物を含む医薬組成物、および哺乳類のアルツハイマー病及びインスリン抵抗性症候群及び２型糖尿病を治療するための薬剤の調整における、これらの化合物の利用
AU2018342751A1 (en) Selective P2X3 modulators
EA018620B1 (ru) ПРОИЗВОДНЫЕ ТИЕНОТРИАЗОЛОДИАЗЕПИНА, АКТИВНЫЕ В ОТНОШЕНИИ Apo A1
PT1354884E (pt) Composto de ciclopenta (d) pirazolo [1,5-a] piramida como antagonista de receptor de crf
JP7153662B2 (ja) 薬理学的に活性な脂環式置換ピラゾロ［１，５－ａ］ピリミジン誘導体
JP2020503288A (ja) 選択的ヤヌスキナーゼ阻害剤としてのアミノピラゾール類
JP2010502618A (ja) セロトニン５−ｈｔ２ａ受容体のモジュレータとしてのベンゾフラン誘導体
KR20230021083A (ko) 면역 조절제
JP2020514341A (ja) 薬理学的に活性なアリール置換ピラゾロ［１，５−ａ］ピリミジン誘導体
JP5894164B2 (ja) クロメン誘導体
CN113387957B (zh) 螺环吲哚酮-吡咯烷碳酸酯化合物和其组合物、制备方法及用途
US9879020B2 (en) GABAA agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
JP2024529508A (ja) ピロロ［２，３－ｂ］ピリジンＰＧＤＨ阻害剤、および製造方法ならびに使用方法
JP2012502977A (ja) ホスホジエステラーゼ阻害薬
BR112019003065B1 (pt) Compostos moduladores do receptor gaba(a) ou sais farmaceuticamente aceitável dos mesmos, composição farmacêutica e forma de dosagem unitária compreendendo ditos compostos e usos terapêuticos dos mesmos
JP2020524135A (ja) 気管支拡張を誘発するためのｒａｃ１阻害剤及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220119

R150 Certificate of patent or registration of utility model

Ref document number: 7013446

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250